These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20199781)

  • 1. [Adverse events after administration of A/H1N1 vaccine to patients].
    Hernández-García I; Haro-Pérez AM; González-Celador R; Sáenz-González Mdel C
    Med Clin (Barc); 2011 Jun; 137(3):136-7. PubMed ID: 20199781
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene].
    Bruun Laursen A
    Ugeskr Laeger; 2013 May; 175(20):1447. PubMed ID: 23833781
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
    Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
    Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute polyarthritis after influenza A (H1N1) immunization.
    Tabache F; El Kartouti A; Naitlhou A; Hassikou H; Tarib A; Baaj M; Cherrah Y
    Joint Bone Spine; 2011 May; 78(3):321-2. PubMed ID: 21444232
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
    Gasparini R; Schioppa F; Lattanzi M; Barone M; Casula D; Pellegrini M; Veitch K; Gaitatzis N
    Int J Clin Pract; 2010 Mar; 64(4):432-8. PubMed ID: 20039974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
    Reynales H; Astudillo P; de Vallière S; Hatz C; Schlagenhauf P; Rath B; Velentgas P; Fariña A; Sales-Carmona V; Groth N
    Vaccine; 2012 Oct; 30(45):6436-43. PubMed ID: 22902681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases.
    Montagnani S; Tuccori M; Lombardo G; Testi A; Mantarro S; Ruggiero E; Blandizzi C
    Ann Pharmacother; 2011 Jan; 45(1):e8. PubMed ID: 21189364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study.
    Heikkinen T; Young J; van Beek E; Franke H; Verstraeten T; Weil JG; Della Cioppa G
    Am J Obstet Gynecol; 2012 Sep; 207(3):177.e1-8. PubMed ID: 22939717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research on the relationship between fever and H1N1 influenza vaccination in students].
    Tao LN; Zhang H; Mao SH
    Zhongguo Yi Miao He Mian Yi; 2010 Jun; 16(3):214-8. PubMed ID: 20726260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
    Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
    Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
    Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one.
    Candela S; Pergolizzi S; Ragni P; Cavuto S; Nobilio L; Di Mario S; Dragosevic V; Groth N; Magrini N;
    Vaccine; 2013 Feb; 31(10):1431-7. PubMed ID: 22766247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine.
    Javelle E; Soulier B; Brosset C; Lorcy S; Simon F
    Vaccine; 2011 Feb; 29(6):1123-5. PubMed ID: 21172376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
    Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.